Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Link Healthcare Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024
Details : NMPA has approved Lidoderm® ("lidocaine 5% patch as lidocaine cataplasms") a local anesthetic for the treatment of Post Herpetic Neuralgia in China.
Product Name : Lidoderm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Lidocaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Link Healthcare Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TPU-006 is an investigational transdermal system that delivers dexmedetomidine, a selective α2-adrenergic agonist, for up to four days from a single application, which is investigated for the treatment of Post Operative Pain.
Product Name : TPU-006
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable